PVLA Stock Forecast & Price Target

Palvella Therapeutics is attractive because its lead asset, QTORIN 3.9% rapamycin anhydrous gel, has already de-risked the core science with Phase 3 SELVA meeting primary and secondary endpoints and the NDA completed on Aug 31, shifting the story from efficacy to execution. The company addresses microcystic lymphatic malformations, a rare disease with no FDA-approved therapy, and its claims-based market work suggests roughly 42K U.S. patients, supporting meaningful commercial upside with modeled first-year launch uptake of about 1,500 patients. Further confidence comes from a differentiated topical platform with low systemic exposure, a focused ~40-rep launch model targeting ~400 centers, and a second program in cVM that adds pipeline breadth and platform value.

Palvella Therapeutics is burdened by substantial regulatory and clinical risk, because its lead mLM program rests on a single-arm, baseline-controlled study in 49 ITT patients while FDA has signaled concerns about the primary endpoint and a relative bioavailability study against oral rapamycin. Its cVM opportunity is even less certain, as TOIVA enrolled only 16 patients, had no prespecified primary endpoint, produced nominal p-values, and still faces an undecided Phase 3 design after Breakthrough Therapy designation was denied in July. Financially, the company held $250.6M in cash and short-term investments at June 30, 2026, but guidance for only at least 12 months of runway, negative FCF through 2028, and Ligand royalties of 8.0% to 9.8% imply dilution risk and limited margin for execution mistakes.